CECOG Academy

www.cecog.org

 

CECOG Academy
F

Case Review of a 78 y/o Man With PDAC: Following OS From the Start of Adjuvant Chemotherapy

By CECOG Academy FEATURING Florian Huemer
By CECOG Academy FEATURING Florian Huemer
117 views
September 7, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

03:38
Lilly Medical Affairs

SERDS: Relevance and Role in Current & Future Treatments for HR+…

Feat. K. Jhaveri

Featured Video

03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri
Pancreas Cancer Academy 2022
10:15

Case Review of a 78 y/o Man With PDAC: Following OS From the Start o…

CECOG Academy

F. Huemer

117 views
14:55

Case Review: Fit Patient With mPDAC

CECOG Academy

H. Taghizadeh

27 views
18:58

1L mPDAC & Sequence Debate: Why Gemcitabine & Nab-Paclitaxel Followe…

CECOG Academy

H. Wasan

19 views
18:36

mPDAC Treatment Debate: FOLFIRINOX Followed by Gemcitabine + Nab-Pac…

CECOG Academy

J. Taieb

20 views
23:12

mPDAC Sequence Debate: Albumin-Bound Paclitaxel / Gemcitabine Follow…

CECOG Academy

G. Prager

26 views
26:54

New 2022 ESMO Guidelines for Pancreatic Cancer

CECOG Academy

T. Conroy

288 views
08:41

Case Review: Borderline Resectable PDAC

CECOG Academy

H. Taghizadeh

60 views
22:45

Borderline PDAC: What Is the Best Neoadjuvant Treatment Concept?

CECOG Academy

T. Macarulla

77 views
17:52

What to Do With PDAC Patients After Secondary Resection?

CECOG Academy

H. Wasan

25 views
31:42

How to Assess Resectability: The Surgeon's View

CECOG Academy

O. Strobel

33 views
23:05

How to Pick the Individual (Neo)adjuvant Treatment Concept in Resect…

CECOG Academy

E. Van Cutsem

171 views
27:28

Personalized Treatment Approach by Molecular Profiling Might Lead to…

CECOG Academy

T. Golan

65 views